• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

DiogenX raises $30M for regenerative diabetes treatment

May 12, 2023 By Sean Whooley

DiogenX logo-fpngDiogenX announced that it completed a $30 million Series A financing round to support its regenerating insulin-producing beta cells.

Marseille, France-based DiogenX aims to use the funds to advance its lead drug candidate into clinical development. The company designed the disease-modifying, recombinant protein to treat patients with type 1 diabetes. It modulates the Wnt/β-catenin signalling pathway to regenerate pancreatic insulin-producing beta cells.

To date, DiogenX achieved in vivo proof of concept, demonstrating efficacy in prevention and reversion settings. It also demonstrated “an unprecedented effect” on human beta cell mass generation, leading to increased functional insulin-producing beta cells.

Data demonstrated well-tolerated long-term exposure to the drug in all preclinical modules. The company says the data suggests the potential for broad clinical utility. This could come in monotherapy and in combination with insulins and therapies that replace or protect beta cells.

DiogenX adds the $30 million round to $4.8 million previously raised in June 2020.

Boehringer Ingelheim Venture Fund (BIVF) led the round. New investors Roche Venture Fund, Eli Lilly and Omnes joined the round as well. Historic investors JDRF T1D Fund and AdBio partners participated, too. As part of the financing, David Evans, investment director at Roche Venture Fund, joins DiogenX’s board of directors.

“We are working to develop a breakthrough therapy to harness the patient’s own remaining endogenous beta cells to increase insulin production and modify the course of type 1 diabetes, potentially eliminating the need for exogenous insulin in some patients,” said Benjamin Charles, CEO of DiogenX. “The successful closing of this financing and the strong consortium of biopharma and diabetes leaders will support DiogenX with the expertise required to advance the development of our lead program towards patients.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Regenerative Medicine Tagged With: DiogenX

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS